Effect of nonsteroidal anti-inflammatory drugs on β-catenin protein levels and catenin-related transcription in human colorectal cancer cells

British Journal of Cancer

Volumn 91, Issue 1, 2004, Pages 153-163

  Gardner, S H ^a   Hawcroft, G ^a   Hull, M A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

catenin; Colorectal cancer cyclin D1; Nonsteroidal anti inflammatory drug

Indexed keywords

BETA CATENIN; CYCLIN D1; DICLOFENAC; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SULFONE; SULINDAC SULFIDE; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; TRANSACTIVATOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG EFFECT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; REPORTER GENE; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; COLORECTAL TUMOR; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BETA CATENIN; CELL DIVISION; COLORECTAL NEOPLASMS; CYCLIN D1; CYTOSKELETAL PROTEINS; DOWN-REGULATION; HUMANS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 3343010645     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601901     Document Type: Article

References (35)

1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvein TK, Schnitzer TJ, for the VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520-1528
2. Boon EMJ, Keller JJ, Wormhoudt TAM, Giardiello FM, Offerhaus GJA, van der Neut R, Pals ST (2004) Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 90: 224-229
3. Bordonaro M, Mariadason JM, Aslam F, Heerdt BG, Augenlicht LH (1999) Butyrate-induced apoptotic cascade in colonic carcinoma cells: modulation of the β-catenin-Tcf pathway and concordance with effects of sulindac and trichostatin A but not curcumin. Cell Growth Diff 10: 713-720
4. Brown WA, Skinner SA, Vogiagis D, O'Brien PE (2001a) Inhibition of β-catenin translocation in rodent colorectal tumors. A novel explanation for the protective effect of nonsteroidal antiinflammatory drugs in colorectal cancer. Dig Dis Sci 46: 2314-2321
5. Brown WA, Skinner SA, Malcontenti-Wilson C, Vogiagis D, O'Brien PE (2001b) Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase-1 or cyclooxygenase-2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 48: 660-666
6. Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, Windsor ACJ, Guillou PJ, Markham AF, Coletta PL, Hull MA (2000) Localisation of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 156: 545-553
7. Dihlmann S, Siermann A, von Knebel Doeberitz M (2001) The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate β-catenin/TCF-4 signaling. Oncogene 20: 645-653
8. Dihlmann S, Klein S, von Knebel Doeberitz M (2003) Reduction of β-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated β-catenin. Mol Cancer Therap 2: 509-516
9. Hawcroft G, D'Amico M, Albanese C, Markham AF, Pestell RG, Hull MA (2002) Indomethacin induces differential expression of β-catenin, γ-catenin and T-cell factor genes in human colorectal cancer cells. Carcinogenesis 23: 101-108
10. Hawcroft G, Gardner SH, Hull MA (2003) Activation of peroxisome proliferator-activated receptor γ does not explain the antiproliferative activity of the nonsteroidal anti-inflammatory drug indomethacin on human colorectal cancer cells. J Pharmacol Exp Therap 305: 632-637
11. Herter P, Kuhnen C, Muller K-M, Wittinghofer A, Muller O (1999) Intracellular distribution of β-catenin in colorectal adenomas, carcinomas and Peutz-Jeghers polyps. J Cancer Res Clin Oncol 125: 297-304
12. Hixson LJ, Alberts DS, Krutzsch M, Einsphar J, Brendel K, Gross PH, Shipp Paranka N, Baier M, Emerson S, Pamukcu R, Burt RW (1994) Anti-proliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 3: 433-438
13. Hull MA, Gardner SH, Hawcroft G (2003) The anti-colorectal cancer activity of the non-steroidal anti-inflammatory drug indomethacin. Cancer Treat Rev 29: 309-320
14. Hwang DH, Fung V, Dannenberg AJ (2002) National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia 4: 91-97
15. Ko SCW, Chapple KS, Hawcroft G, Coletta PL, Markham AF, Hull MA (2002) Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells. Oncogene 21: 7175-7186
16. -/- colon carcinoma. Science 275: 1784-1787
17. Li H, Liu L, David ML, Whitehead CM, Chen M, Fetter JR, Sperl GJ, Pamukcu R, Thompson WJ (2002) Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve β-catenin and cyclin D1 down-regulation. Biochem Pharmacol 64: 1325-1336
18. 1 checkpoint. Mol Cell Biol 16: 6917-6925
19. Martin C, Connelly A, Keku TO, Mountcastle SB, Galanko J, Woosley JT, Schliebe B, Lund PK, Sandler RS (2002) Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology 123: 1770-1777
20. McEntee MF, Chiu CH, Whelan J (1999) Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 20: 635-640
21. ΔNβ-cat mutant mice to treatment with tea, sulindac and 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridine (PhIP). Mutation Res 506-507: 121-127
22. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61: 1733-1740
23. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ, Pamukcu R (1997a) Sulindac sulphone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57: 2909-2915
24. Piazza GA, Rahm AK, Finn TS, Li H, Stoumen AL, Pamukcu R, Ahnen DJ (1997b) Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest and p53 induction. Cancer Res 57: 2452-2459
25. Qiao L, Shiff SJ, Rigas B (1997) Sulindac sulfide inhibits the proliferation of colon cancer cells: diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett 115: 229-234
26. Rice PL, Kelloff J, Sullivan H, Daggers LJ, Beard KS, Kuwada S, Piazza G, Ahnen DJ (2003) Sulindac metabolites induce caspase- and proteasome-dependent degradation of β-catenin protein in human colon cancer cells. Mol Cancer Therap 2: 885-892
27. Shiff SJ, Koutsos MI, Qiao L, Rigas B (1996) Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 222: 179-188
28. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A (1999) The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522-5527
29. Smith M-L, Hawcroft G, Hull MA (2000) The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 36: 664-674
30. Takahashi M, Fukuda K, Sugimura T, Wakabayashi K (1998) β-Catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. Cancer Res 58: 42-46
31. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D, Pamukcu R (2000) Exisulind induction of apoptosis involves guanosine 3′, 5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation and attenuated β-catenin. Cancer Res 60: 3338-3342
32. Wang C, Fu M, D'Amico M, Albanese C, Zhou J-N, Brownlee M, Lisanti MP, Chatterjee VKK, Lazar MA, Pestell RG (2001) Inhibition of cellular proliferation through IκB kinase-independent and peroxisome proliferator-activated receptor γ-dependent repression of cyclin D1. Mol Cell Biol 21: 3057-3070
33. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR (1999) Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96: 7563-7568
34. Wong NACS, Pignatelli M (2002) β-Catenin - a linchpin in colorectal carcinogenesis? Am J Pathol 160: 380-401
35. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S (2002) Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 531: 278-284